Contineum Therapeutics, Inc. Class A Common Stock Total Assets
Contineum Therapeutics, Inc. Class A Common Stock total assets. Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) holds total assets worth $250.37 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CTNM company net worth for the company's overall valuation and market capitalisation.
Total Assets of Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
Total assets of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's total assets have evolved over time, based on quarterly financial data. See CTNM share price today for real-time trading data and today's change.
Contineum Therapeutics, Inc. Class A Common Stock - Asset Composition Analysis
Contineum Therapeutics, Inc. Class A Common Stock Total Assets Breakdown (December 2025)
Contineum Therapeutics, Inc. Class A Common Stock total assets breakdown as of December 2025. Contineum Therapeutics, Inc. Class A Common Stock's total assets of $250.37 Million consist of 96.9% current assets and 3.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CTNM net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Contineum Therapeutics, Inc. Class A Common Stock's current assets represent 96.9% of total assets in 2025, a decrease from 99.0% in 2021.
- Cash Position: Cash and equivalents constituted 27.3% of total assets in 2025, up from 6.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Total Assets
Key competitors of Contineum Therapeutics, Inc. Class A Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Contineum Therapeutics, Inc. Class A Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 37.17 | 24.51 | 6.41 |
| Quick Ratio | 37.17 | 24.51 | 6.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $236.05 Million | $169.62 Million | $40.84 Million |
Contineum Therapeutics, Inc. Class A Common Stock - Advanced Valuation Insights
This section examines the relationship between Contineum Therapeutics, Inc. Class A Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.32 |
| Latest Market Cap to Assets Ratio | 1.17 |
| Asset Growth Rate (YoY) | 30.0% |
| Total Assets | $276.64 Million |
| Market Capitalization | $322.67 Million USD |
Valuation Analysis
Above Book Valuation: The market values Contineum Therapeutics, Inc. Class A Common Stock's assets above their book value (1.17x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Contineum Therapeutics, Inc. Class A Common Stock's assets grew by 30.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
The table below shows the annual total assets of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $276.64 Million | +29.97% |
| 2024-12-31 | $212.85 Million | +63.24% |
| 2023-12-31 | $130.39 Million | +157.50% |
| 2022-12-31 | $50.64 Million | -28.19% |
| 2021-12-31 | $70.52 Million | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more